1,017
Participants
Start Date
December 15, 2021
Primary Completion Date
February 15, 2027
Study Completion Date
February 15, 2027
MRD
ctDNA MRD test
UPMC Hillman Cancer Center, Pittsburgh
WellSpan York Cancer Center, York
Lankenau Medical Center, Wynnewood
Reading Hospital Hematology Oncology, West Reading
University of Maryland St. Joseph Medical Center, Towson
MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital, Baltimore
Meritus Center for Clinical Research, Hagerstown
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
Atrium Health Levine Cancer Institute, Charlotte
FirstHealth Outpatient Cancer Center, Pinehurst
Primsa Health Cancer Institute, Greenville
University of Florida Division of Hematology & Oncology, Gainesville
Mid Florida Cancer Centers, Orange City
Mount Sinai Medical - Comprehensive Cancer Center, Miami Beach
Ballad Health Cancer Center, Kingsport
Columbus NCORP, Columbus
Mercy Medical Center, Cedar Rapids
Marshfield Medical Center Weston, Weston
Metro Minnesota Community Oncology Consortium (MMCORC), Saint Louis Park
Sanford Cancer Center, Sioux Falls
Sanford Roger Maris Cancer Center, Fargo
Edward Cancer Center, Elmhurst
Illinois Cancer Care, Peoria
Missouri Baptist Medical Center, St Louis
University of Kansas Cancer Center, Westwood
Torrance Memorial Hunt Cancer Institute, Torrance
Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology, Mission Hills
Interstate Medical Office Central, Portland
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Center, Toronto
Jewish General Hospital, Montreal
McGill University Health - Glen Site, Montreal
Lead Sponsor
NSABP Foundation Inc
NETWORK
Exact Sciences Corporation
INDUSTRY